Protagonist Therapeutics, Inc. (PTGX) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1237536,
    "name": "Protagonist Therapeutics, Inc.",
    "stock_name": "Protagonist Therapeutics, Inc.",
    "full_name": "Protagonist Therapeutics, Inc.",
    "name_url": "stocks-analysis/protagonist-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "87.33",
    "chg": 2.68,
    "chgp": "3.17%",
    "dir": 1,
    "prev_price": "84.65",
    "mcapval": "3,495.65",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US74366E1029",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "1.47 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/protagonist-therapeutics-inc-1237536-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Protagonist Therapeutics, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Market Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/protagonist-therapeutics-sees-valuation-grade-shift-from-expensive-to-very-expensive-3686311",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ProtagonistTher_valuationdot_3686311.png",
        "date": "2025-11-10 16:10:50",
        "description": "Protagonist Therapeutics, Inc. has experienced a valuation adjustment, reflected in its high P/E ratio of 60 and other elevated financial metrics. The company has outperformed the S&P 500 significantly, with a 67.07% return over the past year and an impressive 106.06% year-to-date, highlighting its strong market position."
      },
      {
        "title": "Is Protagonist Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-protagonist-therapeutics-inc-overvalued-or-undervalued-3637813",
        "imagepath": "",
        "date": "2025-10-21 12:09:26",
        "description": "As of 17 October 2025, the valuation grade for Protagonist Therapeutics, Inc. moved from expensive to very expensive. The company appears to be overvalued based on its high valuation ratios, including a P/E ratio of 60, an EV to EBITDA of 94.50, and a Price to Book Value of 4.89. In comparison, Aurinia Pharmaceuticals, Inc. has a more reasonable P/E ratio of 20.87 and an EV to EBITDA of 12.92, indicating that Protagonist is trading at a significant premium relative to its peers.\n\nDespite a strong year-to-date return of 100.78% compared to the S&P 500's 13.30%, the high valuation metrics suggest that the stock may not be sustainable at its current levels. The substantial disparity in valuation ratios, particularly when compared to its peers, reinforces the conclusion that Protagonist Therapeutics is overvalued...."
      },
      {
        "title": "Protagonist Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Strong Performance Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/protagonist-therapeutics-sees-valuation-grade-shift-from-expensive-to-very-expensive-3641071",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/ProtagonistTher_valuationdot_3641071.png",
        "date": "2025-10-20 17:19:16",
        "description": "Protagonist Therapeutics, Inc. has a notably high valuation compared to its peers, with a P/E ratio of 60 and elevated Price to Book and EV ratios. Despite this, the company has achieved strong performance metrics, including a significant year-to-date return and impressive growth over the past three years."
      },
      {
        "title": "Is Protagonist Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-protagonist-therapeutics-inc-overvalued-or-undervalued-3634681",
        "imagepath": "",
        "date": "2025-10-20 12:26:51",
        "description": "As of 17 October 2025, the valuation grade for Protagonist Therapeutics, Inc. has moved from expensive to very expensive, indicating a significant deterioration in its valuation outlook. The company appears to be overvalued given its high P/E ratio of 60, an EV to EBITDA of 94.50, and a Price to Book Value of 4.89, which are substantially above industry norms. In comparison, Aurinia Pharmaceuticals, Inc. is fairly valued with a P/E of 20.87 and an EV to EBITDA of 12.92, highlighting the stark contrast in valuation metrics.\n\nDespite the overvaluation, Protagonist Therapeutics has delivered impressive returns, with a year-to-date return of 100.78% compared to the S&P 500's 13.30%, and a three-year return of 838.26% against the S&P 500's 81.19%. This strong performance may reflect investor optimism, but the elevated valuation ratios suggest that the stock may not be sustainable at these levels...."
      },
      {
        "title": "Is Protagonist Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-protagonist-therapeutics-inc-overvalued-or-undervalued-3632220",
        "imagepath": "",
        "date": "2025-10-19 12:04:19",
        "description": "As of 17 October 2025, the valuation grade for Protagonist Therapeutics, Inc. moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is overvalued based on its high valuation ratios, including a P/E ratio of 60, an EV to EBITDA of 94.50, and a Price to Book Value of 4.89. In comparison, Aurinia Pharmaceuticals, Inc. has a more reasonable P/E of 20.87 and an EV to EBITDA of 12.92, highlighting the disparity in valuation within the sector.\n\nDespite the company's impressive returns, such as a 100.78% year-to-date return compared to the S&P 500's 13.30%, the high valuation metrics suggest that Protagonist Therapeutics, Inc. may not sustain such performance in the long term. Overall, the company's current valuation appears unsustainable given the substantial premiums over its peers...."
      },
      {
        "title": "Protagonist Therapeutics Hits Day High with 18% Surge Amid Market Decline",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/protagonist-therapeutics-hits-day-high-with-18-surge-amid-market-decline-3620252",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/ProtagonistTher_priceRelatedfactors_3620252.png",
        "date": "2025-10-14 19:32:53",
        "description": "Protagonist Therapeutics, Inc. has seen notable stock activity, with significant gains over various time frames, including a 22.12% increase in the past week and an 81.62% rise over the past year. However, the company faces operational challenges, including a low return on equity and a sharp decline in operating profit."
      },
      {
        "title": "Protagonist Therapeutics Opens with 27.21% Gain Amidst Market Decline",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/protagonist-therapeutics-opens-with-2721-gain-amidst-market-decline-3712367",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ProtagonistTher_gapup_3712367.png",
        "date": "2025-10-14 19:12:40",
        "description": "Protagonist Therapeutics, Inc. experienced a notable stock surge today, contrasting with broader market declines. Despite this positive movement, the company faces significant financial challenges, including low profitability and steep declines in operating profit and net sales. Technical indicators present a mixed outlook for the company's future."
      },
      {
        "title": "Protagonist Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/protagonist-therapeutics-inc-technical-trend-changes-from-bullish-to-mildly-bullish-amid-mixed-signals-3601280",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/ProtagonistTher_technicaldot_3601280.png",
        "date": "2025-10-07 20:40:23",
        "description": "Protagonist Therapeutics, Inc. has recently revised its evaluation amid current market conditions. The company's stock is priced at $64.14, reflecting a notable annual return of 44.56%, significantly outperforming the S&P 500. Technical indicators suggest mixed sentiments, highlighting the company's resilience and strong recovery over various time frames."
      },
      {
        "title": "Is Protagonist Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-protagonist-therapeutics-inc-technically-bullish-or-bearish-3599189",
        "imagepath": "",
        "date": "2025-10-07 12:20:49",
        "description": "As of 3 October 2025, the technical trend for Protagonist Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is also bullish. The daily moving averages indicate a bullish stance. However, the monthly RSI shows a bearish signal, and the KST is mildly bearish on a monthly basis. Bollinger Bands are mildly bullish on both weekly and monthly time frames. Dow Theory and OBV show no trend in either time frame.\n\nIn terms of performance, Protagonist Therapeutics has outperformed the S&P 500 year-to-date with a return of 66.17% compared to 14.18%, and over the past year with a return of 44.56% versus 17.82%. Overall, the current technical stance is mildly bullish, driven primarily by the bullish MACD and moving averages, despite some bearish signals from the RSI and KST...."
      }
    ],
    "total": 25,
    "sid": "1237536",
    "stock_news_url": "https://www.marketsmojo.com/news/protagonist-therapeutics-inc-1237536"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Protagonist Therapeutics, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Market Performance

2025-11-10 16:10:50

Protagonist Therapeutics, Inc. has experienced a valuation adjustment, reflected in its high P/E ratio of 60 and other elevated financial metrics. The company has outperformed the S&P 500 significantly, with a 67.07% return over the past year and an impressive 106.06% year-to-date, highlighting its strong market position.

Is Protagonist Therapeutics, Inc. overvalued or undervalued?

2025-10-21 12:09:26

As of 17 October 2025, the valuation grade for Protagonist Therapeutics, Inc. moved from expensive to very expensive. The company appears to be overvalued based on its high valuation ratios, including a P/E ratio of 60, an EV to EBITDA of 94.50, and a Price to Book Value of 4.89. In comparison, Aurinia Pharmaceuticals, Inc. has a more reasonable P/E ratio of 20.87 and an EV to EBITDA of 12.92, indicating that Protagonist is trading at a significant premium relative to its peers. Despite a strong year-to-date return of 100.78% compared to the S&P 500's 13.30%, the high valuation metrics suggest that the stock may not be sustainable at its current levels. The substantial disparity in valuation ratios, particularly when compared to its peers, reinforces the conclusion that Protagonist Therapeutics is overvalued....

Protagonist Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Strong Performance Metrics

2025-10-20 17:19:16

Protagonist Therapeutics, Inc. has a notably high valuation compared to its peers, with a P/E ratio of 60 and elevated Price to Book and EV ratios. Despite this, the company has achieved strong performance metrics, including a significant year-to-date return and impressive growth over the past three years.

Is Protagonist Therapeutics, Inc. overvalued or undervalued?

2025-10-20 12:26:51

As of 17 October 2025, the valuation grade for Protagonist Therapeutics, Inc. has moved from expensive to very expensive, indicating a significant deterioration in its valuation outlook. The company appears to be overvalued given its high P/E ratio of 60, an EV to EBITDA of 94.50, and a Price to Book Value of 4.89, which are substantially above industry norms. In comparison, Aurinia Pharmaceuticals, Inc. is fairly valued with a P/E of 20.87 and an EV to EBITDA of 12.92, highlighting the stark contrast in valuation metrics. Despite the overvaluation, Protagonist Therapeutics has delivered impressive returns, with a year-to-date return of 100.78% compared to the S&P 500's 13.30%, and a three-year return of 838.26% against the S&P 500's 81.19%. This strong performance may reflect investor optimism, but the elevated valuation ratios suggest that the stock may not be sustainable at these levels....

Is Protagonist Therapeutics, Inc. overvalued or undervalued?

2025-10-19 12:04:19

As of 17 October 2025, the valuation grade for Protagonist Therapeutics, Inc. moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is overvalued based on its high valuation ratios, including a P/E ratio of 60, an EV to EBITDA of 94.50, and a Price to Book Value of 4.89. In comparison, Aurinia Pharmaceuticals, Inc. has a more reasonable P/E of 20.87 and an EV to EBITDA of 12.92, highlighting the disparity in valuation within the sector. Despite the company's impressive returns, such as a 100.78% year-to-date return compared to the S&P 500's 13.30%, the high valuation metrics suggest that Protagonist Therapeutics, Inc. may not sustain such performance in the long term. Overall, the company's current valuation appears unsustainable given the substantial premiums over its peers....

Protagonist Therapeutics Hits Day High with 18% Surge Amid Market Decline

2025-10-14 19:32:53

Protagonist Therapeutics, Inc. has seen notable stock activity, with significant gains over various time frames, including a 22.12% increase in the past week and an 81.62% rise over the past year. However, the company faces operational challenges, including a low return on equity and a sharp decline in operating profit.

Protagonist Therapeutics Opens with 27.21% Gain Amidst Market Decline

2025-10-14 19:12:40

Protagonist Therapeutics, Inc. experienced a notable stock surge today, contrasting with broader market declines. Despite this positive movement, the company faces significant financial challenges, including low profitability and steep declines in operating profit and net sales. Technical indicators present a mixed outlook for the company's future.

Protagonist Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance

2025-10-07 20:40:23

Protagonist Therapeutics, Inc. has recently revised its evaluation amid current market conditions. The company's stock is priced at $64.14, reflecting a notable annual return of 44.56%, significantly outperforming the S&P 500. Technical indicators suggest mixed sentiments, highlighting the company's resilience and strong recovery over various time frames.

Is Protagonist Therapeutics, Inc. technically bullish or bearish?

2025-10-07 12:20:49

As of 3 October 2025, the technical trend for Protagonist Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is also bullish. The daily moving averages indicate a bullish stance. However, the monthly RSI shows a bearish signal, and the KST is mildly bearish on a monthly basis. Bollinger Bands are mildly bullish on both weekly and monthly time frames. Dow Theory and OBV show no trend in either time frame. In terms of performance, Protagonist Therapeutics has outperformed the S&P 500 year-to-date with a return of 66.17% compared to 14.18%, and over the past year with a return of 44.56% versus 17.82%. Overall, the current technical stance is mildly bullish, driven primarily by the bullish MACD and moving averages, despite some bearish signals from the RSI and KST....

View All News